Immunotherapy for Lung Cancer in Smokers vs Non-Smokers — What Your Report Decides, Not Your History

Many patients are not. A targetable EGFR, ALK or ROS1 alteration puts targeted tablets first. Active autoimmune disease, a solid organ transplant, or ongoing high-dose steroids can rule immunotherapy out. Very poor performance status can too. None of these depend on smoking history. Eligibility is decided by the biopsy report, not the cigarette count.

This is the part most families are never told plainly. A large share of lung cancer patients in India are not candidates for immunotherapy in the first line, and the single most common reason is a targetable alteration found on the mutation panel. Never-smokers meet that reason far more often than smokers do. At CION the biomarker report is reviewed by the tumour board before any first-line plan is confirmed, and if the panel has not been run, we say so rather than proceeding around it. You can read what the PD-L1 report itself means on our PD-L1 testing for lung cancer page.

Across groups, yes. Lung cancers that developed in people with a smoking history tend to respond to checkpoint-inhibitor immunotherapy more often than lung cancers in lifelong never-smokers. That is a pattern in populations, not a prediction for you. It does not make smoking beneficial. Tobacco caused the disease being treated.

Mutation load is reported on some panels as tumour mutational burden (TMB). The link between higher mutational burden and checkpoint-inhibitor response is recognised in NCCN and ESMO non-small cell lung cancer guidance. Smoking history is background information for your oncologist, not a test result, and it is never used on its own to grant or refuse treatment.

Because the tumour is more visible to the immune system. Tobacco smoke damages DNA. That damage leaves many mutations. Some mutations make abnormal proteins the body has never seen. Immunotherapy releases the brake on T-cells. A tumour with more abnormal proteins gives those T-cells more to recognise.

1. Tobacco smoke carries carcinogens that damage the DNA inside lung cells.
2. Years of exposure leave thousands of mutations in the cells that become cancer.
3. Some of those mutations produce abnormal proteins called neoantigens.
4. Neoantigens do not appear on healthy cells, so the immune system can read them as foreign.
5. Cancers use checkpoint signals to switch off the T-cells that would attack them.
6. Checkpoint-inhibitor immunotherapy aims to release that brake.
7. A tumour carrying more neoantigens gives the released T-cells more to find.

This is a statement about biology, not a defence of smoking. The same carcinogens that made the tumour more visible also caused it, damaged the lungs it grew in, and strained the heart that has to carry the patient through treatment. Nobody gets a better cancer by smoking. A person with a smoking history simply arrives with a tumour that has a different genetic profile from a never-smoker's, and that profile happens to suit one class of treatment better.

It is also worth being honest about the limits of this pattern. It describes what happens across large groups of patients. It cannot tell you what your tumour will do. In a proportion of patients with heavy smoking histories, immunotherapy does not control the disease at all, which is why the first response scan is planned from the outset and why the plan is written to be changed.

No. Quitting today does not undo the mutations already inside the tumour. Those changes were made years ago and stay in the cancer's DNA. Stopping smoking does not lower your chance of responding. It improves your lung function, your heart, your recovery from procedures, and your ability to stay on treatment.

Patients do ask this, usually quietly, and usually after reading that smokers respond better. The fear is understandable and the answer is clear. The genetic profile of your tumour is already set. It is what the pathologist tested. Cessation changes your body, not the tumour's mutation count.

What stopping smoking actually changes during immunotherapy:

• Breathing you can interpret. Immune-related lung inflammation, called pneumonitis, announces itself as new or worsening breathlessness. A chronic smoker's cough makes that signal much harder to read, for you and for us.
• Fewer chest infections. Infection is one of the commonest reasons a treatment cycle gets postponed.
• Better healing. If a biopsy, a drainage procedure or surgery is part of your plan, wound healing and oxygen delivery both matter.
• Less strain on the heart. This matters more once steroids are needed to manage an immune-related side effect.
• Lower risk of a second tobacco-related cancer later, which is a real consideration when treatment continues for a long time.

WHO and ICMR tobacco-cessation guidance is consistent for people already diagnosed with cancer: stopping helps, at any point in the journey. Ask for a cessation plan at the same visit your treatment is planned rather than treating it as a separate errand. And report any new or changed breathlessness on the same day — call 1800 202 8726 rather than waiting for your next cycle. What to watch for is set out on our pneumonitis risk in lung cancer patients page.

It can still work. Never-smoker lung cancers respond less often as a group, and immunotherapy is still used in never-smokers when the biopsy report supports it. The more common situation is different: a targetable alteration is found, and targeted tablets become the better first treatment. That is a change in order, not a downgrade.

Never-smokers with lung cancer often carry a second burden nobody names: the assumption that they must have smoked. They also tend to be younger and are more often women. None of that changes the pathway. What changes it is the report.

What to ask for if you have never smoked:

• Has a full driver-mutation panel been done, not just one or two genes? Testing only EGFR can miss an ALK or ROS1 alteration that changes the whole plan.
• What is my PD-L1 tumour proportion score? This is reported separately from the mutation panel and both are needed.
• If a driver alteration is found, where does immunotherapy sit later? Sequencing matters, and the answer should be specific to your report.
• If no driver alteration is found, does the PD-L1 score open an immunotherapy option? Never-smoker status alone is not a reason to skip that conversation.
• Is there a clinical trial that fits my report? Trials are informational here, not a promise of enrolment or benefit.

Four things, in this order: the tumour histology, the driver-mutation panel, the PD-L1 tumour proportion score, and your general fitness alongside any autoimmune disease, transplant or steroid use. Smoking history is nowhere on that list. It is context for your oncologist, not a threshold you pass or fail.

TPS = tumour proportion score, the percentage of tumour cells staining for PD-L1. Bands as used in NCCN and ESMO non-small cell lung cancer guidance. Your report may also quote a CPS score, which is calculated differently and is not used the same way in lung cancer. These bands apply identically to smokers and never-smokers.

Immunotherapy is given as day care at CION centres, so there is no overnight stay for a routine cycle. Response-assessment scans, including PET-CT, are coordinated for you at partner imaging centres — CION does not own those scanners, and we tell you where the scan is booked and what it will cost before you go. Cost figures for immunotherapy are indicative, as of August 2026, and move with brand, biosimilar availability, centre and scheme coverage; the detail sits on our cost of immunotherapy for lung cancer page.

Three companion pages pick up where this one stops — what happens when lung cancer has spread to the brain, what immunotherapy after surgery is for, and how the same logic looks in a cancer where it is used very differently.

• Brain Metastases and Immunotherapy in Lung Cancer — read this if a scan has shown spread to the brain, because it changes the sequence of treatment more than smoking history ever does.
• Adjuvant Immunotherapy After Lung Cancer Surgery — for earlier-stage disease that has been operated on, where the eligibility rules are different again.
• Adjuvant Immunotherapy After Melanoma Surgery — a useful contrast: another high-mutation cancer where the same immune logic applies without any tobacco link at all.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is planned, given as day care and monitored across our centres.

Ask for the Report, Not the Assumption

Smoker or never-smoker, the same four things decide your eligibility. We will walk you through all four.